| ||
![]() | ||
This petition is taking off on Change.org, and we think you might be interested in adding your name. Sign now to help: | ||
![]() | ||
![]() | ||
![]() | ||
![]() | ||
![]() | ||
fast track human trials and save lives from cancer | ||
![]() | ||
| ||
![]() | ||
| ||
![]() | ||
ErSO is a new class of drug being developed that has the potential to eradicate estrogen positive breast cancer. This drug could treat more than 70% of all breast cancers! ErSO was developed by scientists at the University of Illinois and is now being developed and tested by Systems Oncology. ErSO is awaiting FDA clearance to start human trials. Those of us living with cancer, especially stage IV metastatic breast cancer (MBC), need trials fast tracked. Your action could very well save lives; 118 of us die from MBC every day in the US alone. First complete this short form and in the "question or comment" section, urge the FDA to "expedite ErSO to human trials; we need new treatments for breast cancer." Then sign the petition. We have love and science on our side. Take that, cancer.... | ||
![]() | ||
| ||
![]() | ||
In this blog, we'll look at how men and women at serving Jesus Christ both at home and abroad. We'll focus on how God is using their work to transform the lives of people all over the world.
Monday, June 27, 2022
Change.org Petition: fast track human trials and save lives from cancer
Subscribe to:
Post Comments (Atom)
MLP April 2025 Newsletter!
In This Issue *Staff Update: A note from Claudia, Jesy, and Teddy *Upcoming Events * WELCOME OUR NEW CHURCHES! *A word from our partners *ML...

-
Genocide, Worker Rights, and White Christian Nationalism NCC Newsletter July 2, 2021 Click here to donate Recent Interview with Jim Winkl...
-
Capital punishment has been a widely debated topic in the United States for many years. In 1972, following the Furman v. Georgia Supreme Co...
-
Proud Boys Lose Control of Their Name to a Black Church They Vandalized By Alan Feuer, New York Times The Proud Boys no longer have control ...
No comments:
Post a Comment